Journal of Postgraduate Medicine
 Open access journal indexed with Index Medicus & ISI's SCI  
Users online: 2526  
Home | Subscribe | Feedback | Login 
About Latest Articles Back-Issues Articlesmenu-bullet Search Instructions Online Submission Subscribe Etcetera Contact
 :: Next article
 :: Previous article 
 :: Table of Contents
 ::  Similar in PUBMED
 ::  Search Pubmed for
 ::  Search in Google Scholar for
 ::  Article in PDF (90 KB)
 ::  Citation Manager
 ::  Access Statistics
 ::  Reader Comments
 ::  Email Alert *
 ::  Add to My List *
* Registration required (free) 

  IN THIS Article
 ::  References

 Article Access Statistics
    PDF Downloaded371    
    Comments [Add]    

Recommend this journal


Year : 2007  |  Volume : 53  |  Issue : 1  |  Page : 3-4

Rapid reversal of anticoagulant bleeding- rFVIIa an option?

Division of Hematology, Dept of Internal Medicine, University Hospital-Rebro, Zagreb, Croatia

Correspondence Address:
Silva Zupancic-Salek
Division of Hematology, Dept of Internal Medicine, University Hospital-Rebro, Zagreb, Croatia

Login to access the Email id

Source of Support: None, Conflict of Interest: None

DOI: 10.4103/0022-3859.30316

Rights and Permissions

How to cite this article:
Zupancic-Salek S. Rapid reversal of anticoagulant bleeding- rFVIIa an option?. J Postgrad Med 2007;53:3-4

How to cite this URL:
Zupancic-Salek S. Rapid reversal of anticoagulant bleeding- rFVIIa an option?. J Postgrad Med [serial online] 2007 [cited 2023 Oct 2];53:3-4. Available from:

Recombinant factor VIIa (rFVIIa) was originally developed and approved for the treatment of bleeding episodes in patients with congenital and acquired hemophilia with inhibiting antibodies towards factor FWm or IX. As FVIII enhances thrombin generation on activated platelets, it may help to improve hemostasis in other situations with coagulation defects or in patients with a preexistent normal coagulation system but who experience excessive bleeding.[1]

In this issue Jψrgen et al .[2] bring up a new database review of cases receiving rFVIIa rescue therapy for uncontrolled bleeding in conjunction with the use of anticoagulant therapy (where traditional therapy had been ineffective).

The use of rFVIIa has been published in case reports and six clinical trials doses of 15-90 mg/kg 2sub . In rat model, rFVIIa normalized the prothrombin time and controlled warfarin-induced bleeding. Also, in 28 healthy volunteers receiving the vitamin K antagonist acenocoumarol to maintain an international normalized ratio (INR) above 2.0, rFVIIa at 5 and 320 mg/kg corrected prothrombin time and INR. The administration of rFVIIa corrects the prothrombin time or INR but still does not always correlate with cessation of bleeding. However, in several case reports and 10 case series, rFVIIa effectively arrested the bleeding in patients who were treated with oral anticoagulants. A small series of patients with intracranial hemorrhage (ICH) due to excess anti-coagulation were successfully treated with 40 mg rFVIIa and with arrest of bleeding and uncomplicated surgical drainage of the hematoma. These observations indicate that rFVIIa may be useful to reverse the effect of warfarin or other vitamin K antagonists in cases where standard therapy has been found insufficient.[3] Reversal of LMWH and UFH-induced bleeding has been done successfully with rFVIIa in a few patients after failure with protamine.[4]

The application of rFVIIa as an antidote and rescue agent in anticoagulant patients with life-threatening bleeding, in whom standard hemostatic treatments have failed is interesting and its possibilities are reported by Jψrgen, et al .[2] There are several limitations of the report like small number of patients and heterogenons; different anticoagulants, variable description of bleeding and treatment with various hemostatics. In these patients there have been other hemostatic failures. We could even be sure that rFVIIa alone improved hemostasis because they have got antidotes/blood products. But it is obvious that standard treatment schedules were unsuccessful in stopping the bleeding.

RFVIIa was given as a rescue and reversed the anticoagulant action of LMWH, UFH, coumadin and warfarin. Taken together these data create a great interest in the use of rFVIIa as a potential agent to reverse anticoagulant effects. We still need more clinical trials to assess the full potential of rFVIIa.

 :: References Top

1.Roberts HR, Monroe DM, White GC. The use of recombinant factor VIIa in the treatment of bleeding disorders. Blood 2004;104:3858-64.  Back to cited text no. 1  [PUBMED]  [FULLTEXT]
2.Ingerslev J, Vanek T, Culic S. Use of recombinant factor VIIa for emergency reversal of anticoagulation. J Postgrad Med 2007;53: 17-22.  Back to cited text no. 2    
3.Levi M, Peters M, Büller HR. Efficacy and safety of recombinant factor VIIa for treatment of several bleeding: A Systematic review. Crit Care Med 2005;33:883-90.  Back to cited text no. 3    
4.Hamley JP. Warfarin reversal. J Clin Pathol 2004;57:1132-9.  Back to cited text no. 4    


Print this article  Email this article
Previous article Next article
Online since 12th February '04
© 2004 - Journal of Postgraduate Medicine
Official Publication of the Staff Society of the Seth GS Medical College and KEM Hospital, Mumbai, India
Published by Wolters Kluwer - Medknow